Measurement of Physical Activity by Actigraphy in Infants and Young Children with Pulmonary Arterial Hypertension - 08/11/23
, Delphine Yung, MD 2, Stephanie Handler, MD 3, Rachel K. Hopper, MD 4, Jeff Fineman, MD 5, Grace Freire, MD 6, Nidhy Varghese, MD 7, Mary P. Mullen, MD, PhD 8, Usha S. Krishnan, MD 9, Eric Austin, MD 10, Lori Silveira, PhD 11, D. Dunbar Ivy, MD 11Abstract |
Objective |
To evaluate the feasibility, tolerability, and adherence with wearable actigraphy devices among infants and children with pulmonary arterial hypertension (PAH).
Study design |
This multicenter, prospective, observational study included children ages 0-6 years with and without PAH. Participants wore the ActiGraph wGT3X-BT on the hip and FitBit Inspire on the wrist during waking hours for 14 days. Steps, vector magnitude counts per minute, activity intensity, heart rate, and heart rate variability were compared between groups.
Results |
Forty-seven participants (18 PAH, 29 control) were enrolled from 10 North American sites. PAH patients were mostly functional class II (n = 16, 89%) and treated with oral medications at the time of enrollment. The number of wear days was not significantly different between the groups (ActiGraph: 10 [95% CI: 5.5, 12.2] in PAH vs 8 [4, 12] in control, P = .20; FitBit 13 [10, 13.8] in PAH vs 12 [8, 14] in control, P = .87). Complete data were obtained in 81% of eligible ActiGraph participants and 72% of FitBit participants. PAH participants demonstrated fewer steps, lower vector magnitude counts per minute, more sedentary activity, and less intense physical activity at all levels compared with control participants. No statistically significant differences in heart rate variability were demonstrated between the 2 groups.
Conclusions |
Measurement of physical activity and other end points using wearable actigraphy devices was feasible in young children with PAH. Larger studies should determine associations between physical activity and disease severity in young patients with PAH to identify relevant end points for pediatric clinical trials.
Le texte complet de cet article est disponible en PDF.Keywords : wearables, 6-minute walk test, clinical trials
Abbreviations : CPM, HRV, 6MWD, PAH
Plan
Vol 262
Article 113639- novembre 2023 Retour au numéro
Article précédent
- Neurodevelopmental Correlates of Brain Magnetic Resonance Imaging Abnormalities in Extremely Low-birth-weight Infants
- Silvia Martini, Jacopo Lenzi, Vittoria Paoletti, Monica Maffei, Francesco Toni, Anna Fetta, Arianna Aceti, Duccio Maria Cordelli, Mariagrazia Zuccarini, Annalisa Guarini, Alessandra Sansavini, Luigi Corvaglia
- Duffy-Null Phenotype-Associated Neutropenia is the Most Common Etiology for Leukopenia/Neutropenia Referrals to a Tertiary Children's Hospital
- Kelsey Gay, Kristopher Dulay, Yaddanapudi Ravindranath, Süreyya Savaşan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?